Adicet Bio

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Adicet Bio and other ETFs, options, and stocks.

About ACET

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. 

CEO
Chen Schor
CEOChen Schor
Employees
102
Employees102
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
2014
Founded2014
Employees
102
Employees102

ACET Key Statistics

Market cap
90.06M
Market cap90.06M
Price-Earnings ratio
-0.83
Price-Earnings ratio-0.83
Dividend yield
Dividend yield
Average volume
105.72K
Average volume105.72K
High today
$9.75
High today$9.75
Low today
$9.26
Low today$9.26
Open price
$9.33
Open price$9.33
Volume
44.34K
Volume44.34K
52 Week high
$17.44
52 Week high$17.44
52 Week low
$6.01
52 Week low$6.01

Stock Snapshot

The current Adicet Bio(ACET) stock price is $9.59, with a market capitalization of 90.06M. The stock trades at a price-to-earnings (P/E) ratio of -0.83.

As of 2026-09-06, Adicet Bio(ACET) stock has fluctuated between $9.26 and $9.75. The current price stands at $9.59, placing the stock +3.6% above today's low and -1.6% off the high.

Adicet Bio(ACET) shares are trading with a volume of 44.34K, against a daily average of 105.72K.

During the past year, Adicet Bio(ACET) stock moved between $6.01 at its lowest and $17.44 at its peak.

During the past year, Adicet Bio(ACET) stock moved between $6.01 at its lowest and $17.44 at its peak.

ACET News

Zacks 3d
Wall Street Analysts See a 258.21% Upside in Adicet Bio: Can the Stock Really Move This High? - Zacks Investment Research

...

Wall Street Analysts See a 258.21% Upside in Adicet Bio: Can the Stock Really Move This High? - Zacks Investment Research
TipRanks 5d
Adicet Bio completes prula-cel Phase 1 SLE analysis

Adicet Bio ( (ACET) ) just unveiled an update. On September 1, 2026, Adicet Bio reported completion of the last patient visit for the planned Phase 1 safety an...

TipRanks 5d
Adicet Bio completes last patient visit for analysis of prula-cel in lupus

Adicet Bio (ACET) announced completion of the last patient visit for the planned Phase 1 safety and efficacy analysis of prulacabtagene leucel – prula-cel – in...

Analyst ratings

100%

of 6 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own ACET. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.